Cardio-Rheumatology: Two Collaborating Disciplines to Deal with the Enhanced Cardiovascular Risk in Autoimmune Rheumatic Diseases

Author(s): Antonis S. Manolis*, Athanasios G. Tzioufas

Journal Name: Current Vascular Pharmacology

Volume 18 , Issue 6 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

In Part 1 of this Thematic Issue entitled “Systemic Autoimmune Rheumatic Diseases and Cardiology”, a panel of specialists and experts in cardiology, rheumatology, immunology and related fields discussed the cardiovascular complications of spondyloarthritides, rheumatoid arthritis, Sjogren’s syndrome and vasculitides, as well as relevant cardiovascular issues related to non-biologic and biologic disease-modifying anti-rheumatic drugs (DMARDs), and provided their recommendations for prevention and management of these complications. In part 2 of this Thematic Issue, experts discuss the enhanced cardiovascular risk conferred by additional autoimmune rheumatic diseases (ARDs), including systemic lupus erythematosus, the antiphospholipid syndrome, psoriasis and psoriatic arthritis and juvenile idiopathic arthritis. These, and the previous articles, place inflammation as the key common link to explain the enhanced risk of cardiovascular complications in patients with ARDs. It follows that treatment should probably target inflammation. From all these contemporary reviews, the conclusion that is derived further supports the notion of the emerging field of Cardio- Rheumatology where physicians and experts from these two disciplines collaborate in risk stratification and optimization of preventive strategies and drug therapies in patients with ARDs.

Keywords: Autoimmune rheumatic disease, cardiovascular disease, cardiorheumatology, systemic lupus erythematosus, psoriasis, psoriatic arthritis, antirheumatic drugs, cardiovascular imaging, coronary artery disease, acute coronary syndromes, atherosclerosis, myocardial infarction, stroke, antiphospholipid syndrome, juvenile idiopathic arthritis.

[1]
England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ 2018; 361: k1036.
[http://dx.doi.org/10.1136/bmj.k1036] [PMID: 29685876]
[2]
Lee KS, Kronbichler A, Eisenhut M, Lee KH, Shin JI. Cardiovascular involvement in systemic rheumatic diseases: An integrated view for the treating physicians. Autoimmun Rev 2018; 17(3): 201-14.
[http://dx.doi.org/10.1016/j.autrev.2017.12.001] [PMID: 29353099]
[3]
Mankad R. Atherosclerotic vascular disease in the autoimmune rheumatologic patient. Curr Atheroscler Rep 2015; 17(4): 497.
[http://dx.doi.org/10.1007/s11883-015-0497-6] [PMID: 25721102]
[4]
Melissaropoulos K, Bogdanos D, Dimitroulas T, Sakkas LI, Kitas GD, Daoussis D. Primary sjögren’s syndrome and cardiovascular disease. Curr Vasc Pharmacol 2020; 18(5): 447-54.
[PMID: 31995009]
[5]
Fragoulis GE, Panayotidis I, Nikiphorou E. Cardiovascular risk in rheumatoid arthritis and mechanistic links: from pathophysiology to treatment. Curr Vasc Pharmacol 2019; 18(5): 431-46.
[http://dx.doi.org/10.2174/1570161117666190619143842] [PMID: 31258091]
[6]
Soulaidopoulos S, Madenidou AV, Daoussis D, et al. Cardiovascular disease in the systemic vasculitides. Curr Vasc Pharmacol 2020; 18(5): 463-72.
[PMID: 32000652]
[7]
Papagoras C, Voulgari P, Drosos A. Cardiovascular disease in the spondyloarthritides. Curr Vasc Pharmacol 2019; 18(5): 473-87.
[PMID: 31330576]
[8]
Mourouzis IS, Manolis AS, Pantos C. Cardiovascular risk of synthetic, non-biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Curr Vasc Pharmacol 2019; 18(5): 455-62.
[http://dx.doi.org/10.2174/1570161117666190930113837] [PMID: 31566134]
[9]
Drakopoulou M, Soulaidopoulos S, Oikonomou G, Toutouzas K, Tousoulis D. Cardiovascular effects of biologic disease-modifying anti-rheumatic drugs (DMARDs). Curr Vasc Pharmacol 2020; 18(5): 488-06.
[http://dx.doi.org/10.2174/1570161118666200214115532] [PMID: 32056527]
[10]
Atzeni F, Nucera V, Gerratana E, et al. Cardiovascular consequences of autoimmune rheumatic diseases. Curr Vasc Pharmacol 2020; 18(6): 566-79.
[PMID: 31985379]
[11]
Kostopoulou M, Nikolopoulos D, Parodis I, Bertsias G. Cardiovascular disease in systemic lupus erythematosus: recent data on epidemiology, risk factors and prevention. Curr Vasc Pharmacol 2020; 18(6): 549-65.
[PMID: 31880245]
[12]
Polytarchou K, Varvarousis D, Manolis AS. Cardiovascular Disease in antiphospholipid syndrome. Curr Vasc Pharmacol 2020; 18(6): 538-48.
[PMID: 31530257]
[13]
Kapniari E, Papadimitriou P, Dalamaga M, et al. Investigating the link between psoriasis and cardiovascular disease: current evidence, therapeutic implications and perspectives. Curr Vasc Pharmacol 2020; 18(6): 592-609.
[14]
Arsenaki E, Georgakopoulos P, Mitropoulou P, et al. Cardiovascular disease in Juvenile Idiopathic Arthritis. Curr Vasc Pharmacol 2020; 18(6): 580-91.
[PMID: 32268865]
[15]
Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017; 76(1): 17-28.
[http://dx.doi.org/10.1136/annrheumdis-2016-209775] [PMID: 27697765]
[16]
Ntusi NAB, Francis JM, Gumedze F, et al. Cardiovascular magnetic resonance characterization of myocardial and vascular function in rheumatoid arthritis patients. Hellenic J Cardiol 2019; 60(1): 28-35.
[http://dx.doi.org/10.1016/j.hjc.2018.01.008] [PMID: 29369795]
[17]
Atzeni F, Corda M, Gianturco L, Porcu M, Sarzi-Puttini P, Turiel M. Cardiovascular imaging techniques in systemic rheumatic diseases. Front Med (Lausanne) 2018; 5: 26.
[http://dx.doi.org/10.3389/fmed.2018.00026] [PMID: 29497612]
[18]
Manolis AS, Manolis TA, Melita H. Atherosclerosis: an athero-thrombo-inflammatory disease. Hosp Chron 2012; 7(4): 195-201.
[19]
Manolis AA, Manolis TA, Melita H, Manolis AS. Psoriasis and cardiovascular disease: the elusive link. Int Rev Immunol 2019; 38(1): 33-54.
[http://dx.doi.org/10.1080/08830185.2018.1539084] [PMID: 30457023]
[20]
Mackey RH, Kuller LH, Moreland LW. Inflammatory joint diseases and atherosclerosis: time to look beyond the ‘lipid paradox’. Curr Opin Lipidol 2019; 30(4): 342-9.
[http://dx.doi.org/10.1097/MOL.0000000000000620] [PMID: 31145122]
[21]
Manolis AS, Tzioufas AG. Cardio-rheumatology: cardiovascular complications in systemic autoimmune rheumatic diseases is inflammation the common link and target? Curr Vasc Pharmacol 2020; 18(5): 425-30.
[PMID: 32410564]
[22]
Stea EA, Routsias JG, Clancy RM, Buyon JP, Moutsopoulos HM, Tzioufas AG. Anti-La/SSB antiidiotypic antibodies in maternal serum: a marker of low risk for neonatal lupus in an offspring. Arthritis Rheum 2006; 54(7): 2228-34.
[http://dx.doi.org/10.1002/art.21954] [PMID: 16802359]
[23]
Manolis AA, Manolis TA, Melita H, Manolis AS. Congenital heart block: Pace earlier (Childhood) than later (Adulthood). Trends Cardiovasc Med 2020; 30(5): 275-86.
[PMID: 31262557]
[24]
Taylor EB, Wolf VL, Dent E, Ryan MJ. Mechanisms of hypertension in autoimmune rheumatic diseases. Br J Pharmacol 2019; 176(12): 1897-913.
[http://dx.doi.org/10.1111/bph.14604] [PMID: 30714094]
[25]
Bartoloni E, Alunno A, Gerli R. Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases. Nat Rev Cardiol 2018; 15(1): 33-44.
[http://dx.doi.org/10.1038/nrcardio.2017.118] [PMID: 28836617]
[26]
Sule S, Fontaine K. Metabolic syndrome in adults with a history of juvenile arthritis. Open Access Rheumatol 2018; 10: 67-72.
[http://dx.doi.org/10.2147/OARRR.S157229] [PMID: 29922101]
[27]
Aulie HA, Estensen ME, Selvaag AM, Lilleby V, Flatø B, Aakhus S. Arterial properties in adults with long-lasting active juvenile idiopathic arthritis compared to healthy controls. Pediatr Rheumatol Online J 2018; 16(1): 85.
[http://dx.doi.org/10.1186/s12969-018-0302-5] [PMID: 30594204]
[28]
Anderson JH, Anderson KR, Aulie HA, et al. Juvenile idiopathic arthritis and future risk for cardiovascular disease: a multicenter study. Scand J Rheumatol 2016; 45(4): 299-303.
[http://dx.doi.org/10.3109/03009742.2015.1126345] [PMID: 26854592]
[29]
Koca B, Sahin S, Adrovic A, Barut K, Kasapcopur O. Cardiac involvement in juvenile idiopathic arthritis. Rheumatol Int 2017; 37(1): 137-42.
[http://dx.doi.org/10.1007/s00296-016-3534-z] [PMID: 27417551]
[30]
Raab A, Sengler C, Niewerth M, et al. Comorbidity profiles among adult patients with juvenile idiopathic arthritis: results of a biologic register. Clin Exp Rheumatol 2013; 31(5): 796-802.
[PMID: 23557722]
[31]
Van der Heiden K, Cuhlmann S, Luong A, Zakkar M, Evans PC. Role of nuclear factor kappaB in cardiovascular health and disease. Clin Sci (Lond) 2010; 118(10): 593-605.
[http://dx.doi.org/10.1042/CS20090557] [PMID: 20175746]
[32]
van Loo G, Beyaert R. Negative regulation of NF-κB and its involvement in rheumatoid arthritis. Arthritis Res Ther 2011; 13(3): 221.
[http://dx.doi.org/10.1186/ar3324] [PMID: 21639951]
[33]
Brown KD, Claudio E, Siebenlist U. The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther 2008; 10(4): 212.
[http://dx.doi.org/10.1186/ar2457] [PMID: 18771589]
[34]
Prasad M, Hermann J, Gabriel SE, et al. Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol 2015; 12(3): 168-76.
[http://dx.doi.org/10.1038/nrcardio.2014.206] [PMID: 25533796]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 6
Year: 2020
Page: [533 - 537]
Pages: 5
DOI: 10.2174/1570161118666200721145718

Article Metrics

PDF: 51
HTML: 8
PRC: 1